Regeneron Pharmaceuticals Inc (REGN) has declared a quarterly dividend of $0.88 per share, reinforcing its commitment to returning value to shareholders. The dividend will be payable to shareholders of record on December 4, 2025, with an ex-dividend date set for November 19, 2025.
Currently, Regeneron boasts a dividend yield of 0.54%, reflecting the annual income relative to its stock price. This decision highlights the company's ongoing strategy of providing regular income to investors, as it continues to generate robust cash flow through its innovative biotechnology portfolio.
Headquartered in Tarrytown, New York, Regeneron engages in the discovery, development, and commercialization of medicines for serious diseases. Its marketed products include EYLEA, Dupixent, and Libtayo, among others. As of November 8, 2025, the company holds a market capitalization of $68.0 billion, with a price-to-earnings ratio of 14.85 and an earnings per share of 41.78. Upcoming earnings are anticipated on July 29, 2026, with estimates of $11.20 EPS and $3.7 billion in revenue.
Such decisions reflect Regeneron's commitment to maintaining a consistent dividend policy, which can be appealing to income-focused investors. However, it is important for shareholders to consider the company's financial health and dividend history when evaluating the sustainability of these payments.